Ziresovir (Synonyms: AK0529; RO-0529)

Name: Ziresovir
Brand: MedChemExpress
SKU: HY-109142
Rating: 5.0 (3 reviews)

Cat. No.: HY-109142 Purity: 95.51%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC₅₀=3 nM) and highlights pharmacokinetics in animal species.

For research use only. We do not sell to patients.

Ziresovir Chemical Structure

CAS No. : 1422500-60-4

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 338	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 338	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 350	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 550	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 990	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 1650	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 2250	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

3 Publications Citing Use of MCE Ziresovir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

RSV F protein (respiratory syncytial virus fusion protein)^[1] EC50: 3 nM (RSV F)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HEp-2	CC₅₀	> 100 μM Compound: RO-0529; AK0529	Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 5 days by CCK-8 assay Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 5 days by CCK-8 assay	[PMID: 31194544]

In Vitro

Ziresovir shows different efficacy in Wild Type (WT) and Mutant Strains RSV with EC₅₀/EC₉₀ values (μM) of 0.003/0.005 (WT), 2.1/10.0 (D486N), and >10/>10 (D489A), respectively^[1].
RO-0529 (100 nM; 4 d) inhibits RSV F protein-induced cell–cell fusion process, and suppresses the syncytia formation induced by the RSV F protein^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ziresovir (12.5 mg/kg, 50 mg/kg; p.o.; twice daily; 4 d) results reduction of RSV titer in mouse lung^[1].
Ziresovir (10 mg/kg; p.o.; single dose) exhibits good oral exposure and bioavailability with F(%) of 32% in male Wistar-Han rats^[1].
Ziresovir (150 mg/kg; p.o.; single dose) demonstrates a high tissue distribution to lung than plasma in CD-1 Mice^[1].
Pharmacokinetics of Ziresovir in male Wistar-Han rats^[1]

Dose (mg/kg)	AUC_0-24h(p.o.) (ng·h/mL)	CL (mL/min/kg)	T_1/2(i.v.) (h)	V_ss (L/kg)	F (%)
2 mg/kg (iv) or 10 mg/kg (po)	906	58	1.2	3.9	32

Pharmacokinetics of Ziresovir in CD-1 Mice^[1]

Dose (mg/kg)	AUC_0-24h(p.o.) (μg·h/L)	tissue/lasma AUC_0-24h ratio (μg·h/L)	T_1/2 (h)	T_max (h)	C_max (μg/L)
plasma	8,380	1	1.02	0.25	5090
lung	72,400	8.6	3.31	1	22700

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice infected by RSV^[1]
Dosage:	12.5 mg/kg, 50 mg/kg
Administration:	Oral gavage; twice daily; 4 days
Result:	Resulted >1 log unit of viral titer reduction in the lung of infected mice at the dose level as low as 12.5 mg/kg. Reduced viral titer to 1.9 log units compared to vehicle at 50 mg/kg dose.

Clinical Trial

Molecular Weight

439.53

Formula

C₂₂H₂₅N₅O₃S

CAS No.

1422500-60-4

Appearance

Solid

Color

White to off-white

SMILES

NC1(COC1)CNC2=NC(N(CC3)CC4=CC=CC=C4S3(=O)=O)=NC5=C2C=C(C)C=C5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (284.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2752 mL	11.3758 mL	22.7516 mL
5 mM	0.4550 mL	2.2752 mL	4.5503 mL
10 mM	0.2275 mL	1.1376 mL	2.2752 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 95.51%

Select Batch:

Data Sheet (282 KB) SDS (251 KB)

COA (254 KB) HNMR (265 KB) RP-HPLC (245 KB)

Handling Instructions (2659 KB)

References

[1]. Zheng X, et al. Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor. J Med Chem. 2019 Jul 11;62(13):6003-6014. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2752 mL	11.3758 mL	22.7516 mL	56.8789 mL
	5 mM	0.4550 mL	2.2752 mL	4.5503 mL	11.3758 mL
	10 mM	0.2275 mL	1.1376 mL	2.2752 mL	5.6879 mL
	15 mM	0.1517 mL	0.7584 mL	1.5168 mL	3.7919 mL
	20 mM	0.1138 mL	0.5688 mL	1.1376 mL	2.8439 mL
	25 mM	0.0910 mL	0.4550 mL	0.9101 mL	2.2752 mL
	30 mM	0.0758 mL	0.3792 mL	0.7584 mL	1.8960 mL
	40 mM	0.0569 mL	0.2844 mL	0.5688 mL	1.4220 mL
	50 mM	0.0455 mL	0.2275 mL	0.4550 mL	1.1376 mL
	60 mM	0.0379 mL	0.1896 mL	0.3792 mL	0.9480 mL
	80 mM	0.0284 mL	0.1422 mL	0.2844 mL	0.7110 mL
	100 mM	0.0228 mL	0.1138 mL	0.2275 mL	0.5688 mL

Ziresovir Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Ziresovir (Synonyms: AK0529; RO-0529)

Customer Review

Ziresovir Related Antibodies

3 Publications Citing Use of MCE Ziresovir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Ziresovir Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ziresovir Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report